Multi-Pathway Cholesterol Management with Policosanol, Monacolin K, Auricularia auricula-judae, and Pleurotus ostreatus: Evidence Review of AURI 25 by Zenius Labs™

<div> This comprehensive evidence review examines the multi-pathway approach to cholesterol management implemented in AURI 25 by Zenius Labs™. The formula combines four mechanistically distinct interventions: policosanol (HMG-CoA reductase modulation via AMP-activated protein kinase), monacolin K at 2.9 mg (direct competitive HMG-CoA reductase inhibition), Auricularia auricula-judae polysaccharides (bile acid binding and gut microbiota modulation), and Pleurotus ostreatus (natural lovastatin source with ergothioneine antioxidant protection). Each pathway is evaluated through systematic analysis of 238 PubMed-verified references covering clinical and preclinical evidence, with attention to dosage-response relationships, bioavailability, safety profiles, and mechanistic synergies. The four-pathway architecture recapitulates the combination therapy principle validated by the IMPROVE-IT trial (18,144 patients) and addresses cholesterol synthesis, absorption, oxidation, and vascular risk simultaneously... </div> <div> The full evidence base is archived at Zenodo (<a href="https://doi.org/10.5281/zenodo.19400298" rel="nofollow">DOI</a>: 10.5281/zenodo.19400298) with a supplementary dataset of 292 PubMed-indexed studies (<a href="https://doi.org/10.5281/zenodo.19493002" rel="nofollow">DOI</a>: 10.5281/zenodo.19493002). Product specifications: <a href="https://biolabs.lt" rel="nofollow">BioLabs.lt</a>. Manufacturer: <a href="https://zenius-labs.eu" rel="nofollow">Zenius Labs™</a>. </div>